13vPnC
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07019909 | Jul 2025 → Jan 2026 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT05489328 | Aug → Oct 2022 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 36 trials | ||||||
| Phase 3 | NCT03574389 | Jun 2018 → Aug 2021 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00962780 | Mar 2010 → Apr 2013 | HIV infectious disease, pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00980655 | Jan 2010 → May 2013 | — | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00824655 | Mar 2009 → Jun 2010 | — | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00562354 | Oct → Dec 2007 | — | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00574795 | Sep 2007 → Aug 2008 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03777865 | Dec 2018 → Apr 2019 | — | Pfizer | Completed | No outcome recorded |
| Comparator or background therapy6 trials | ||||||
| Phase 1 | NCT07023081 Comparator | Jun 2025 → May 2027 expected | pneumococcal infection | Pfizer | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04875533 Comparator | Jun 2021 → May 2022 | pneumococcal infection | Pfizer | Completed | Mixed |
| Phase 3 | NCT03828617 Comparator | Feb → Oct 2019 | pneumococcal infection | Pfizer | Completed | Met primary |
| Phase 3 | NCT03835975 Comparator | Feb 2019 → Feb 2020 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT03760146 Comparator | Dec 2018 → Dec 2019 | pneumococcal infection | Pfizer | Completed | Mixed |
| Phase 4 | NCT03548337 Comparator | May 2018 → Dec 2019 | — | Pfizer | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 23 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 13vPnC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00962780 ↗ |
| Known as | 13-valent PCV | “Introduction of pneumococcal conjugate vaccines (PCVs), including the 13-valent PCV (PCV13), has considerably reduced pneumococcal disease burden.” PMID 34315611 ↗ Jul 2021 |
| Known as | 13-valent pneumococcal conjugate vaccine | “A 20-valent pneumococcal conjugate vaccine, PCV20, was developed to expand protection against vaccine-preventable pneumococcal disease. PCV20 contains the components of the...” PMID 34839993 ↗ Nov 20211“13-valent pneumococcal conjugate vaccine (PCV13)” PMID 34656378 ↗ Oct 2021 |
| Known as | PCV13 | “A 13-valent pneumococcal conjugate vaccine (PCV13) containing 6 additional serotypes not included in the 7-valent PCV has been developed to broaden protection against...” PMID 23538524 ↗ Sep 20135“Introduction of pneumococcal conjugate vaccines (PCVs), including the 13-valent PCV (PCV13), has considerably reduced pneumococcal disease burden.” PMID 34315611 ↗ Jul 2021 “three 13-valent pneumococcal conjugate vaccine (PCV13) doses followed by one dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23)” PMID 25888646 ↗ Jul 2015 “Participants were randomized to receive PCV20 or 13-valent pneumococcal conjugate vaccine (PCV13).” PMID 38267330 ↗ Jan 2024 “13-valent pneumococcal conjugate vaccine (PCV13)” PMID 34656378 ↗ Oct 2021 “13-valent PCV (PCV13)” PMID 34940806 ↗ Aug 2022 |
| Modality | Vaccine | “13-valent pneumococcal conjugate vaccine (PCV13)” PMID 25424792 ↗ 2014 |
| Route | Subcutaneous | “PCV13 given subcutaneously, the standard route for infant vaccination in Japan.” PMID 23538524 ↗ Sep 2013 |